FDA Advisory Committee Votes in Support of Favorable Benefit-Risk Profile for neffy® (Intranasal (IN) Epinephrine) for the Treatment of Allergic Reactions (Type 1), Including Anaphylaxis May 11, 2023 by Leave a Comment Last Updated on May 11, 2023 by [#item_full_content] Share this:TwitterFacebookMorePrintLike this:Like Loading... Related Spread the word
